Name: ERNEXA THERAPEUTICS INC (ERNA) Stock
Brand: ERNEXA THERAPEUTICS INC
Rating: 3.5 (3 reviews)

ERNA Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Chartmill - Mentions: FMFC FLS LRN FI ...

Keep an eye on the top gainers and losers in Wednesday's session.

10 days ago - By: Chartmill - Mentions: PLUG NOK NVDA FGL ...

Curious about the most active stocks on Wednesday?

a day ago - By: Benzinga - Mentions: CDXS WORX IRD SINT ...

12 Health Care Stocks Moving In Friday's After-Market Session

3 days ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

10 days ago - By: Benzinga - Mentions: ALGN EBS GH GKOS ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

10 days ago - By: Stocktwits - Mentions: VXF

ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials

10 days ago - By: Chartmill - Mentions: FLS LRN AXGN FI ...

Keep an eye on the top gainers and losers in Wednesday's session.

10 days ago - By: Chartmill - Mentions: FLS LRN CSIQ FI ...

Let's uncover which stocks are experiencing notable gaps during today's session.

11 days ago - By: Chartmill - Mentions: LRN FI FGL VRNS ...

Get insights into the top gainers and losers of Wednesday's pre-market session.

11 days ago - By: Cellipont Bioservices

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

a month ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

a month ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

2 months ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

2 months ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

2 months ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

5 months ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

5 months ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

5 months ago - By: Yahoo Finance

Ernexa Therapeutics announces 1-for-15 reverse stock split

5 months ago - By: Yahoo Finance - Mentions: WFC MS SHOP GILD ...

Wells Fargo CFO says trading to be bigger driver of NII

5 months ago - By: Stocktwits - Mentions: VXF VTI

Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish

5 months ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

5 months ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

6 months ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

7 months ago - By: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

7 months ago - By: Ernexa Therapeutics Inc.

ERNEXA THERAPEUTICS INC (ERNA) Stock News

ERNA Latest News, Press Relases and Analysis

Keep an eye on the top gainers and losers in Wednesday's session.

Curious about the most active stocks on Wednesday?

12 Health Care Stocks Moving In Friday's After-Market Session

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

12 Health Care Stocks Moving In Wednesday's After-Market Session

ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials

Keep an eye on the top gainers and losers in Wednesday's session.

Let's uncover which stocks are experiencing notable gaps during today's session.

Get insights into the top gainers and losers of Wednesday's pre-market session.

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Ernexa Therapeutics announces 1-for-15 reverse stock split

Wells Fargo CFO says trading to be bigger driver of NII

Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Ernexa Therapeutics Closes New Funding Round